Annual CFF
$250.78 M
+$157.91 M+170.04%
December 31, 2024
Summary
- As of March 10, 2025, VRNA annual cash flow from financing activities is $250.78 million, with the most recent change of +$157.91 million (+170.04%) on December 31, 2024.
- During the last 3 years, VRNA annual CFF has risen by +$256.90 million (+4199.71%).
- VRNA annual CFF is now at all-time high.
Performance
VRNA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$94.16 M
+$101.24 M+1428.59%
December 31, 2024
Summary
- As of March 10, 2025, VRNA quarterly cash flow from financing activities is $94.16 million, with the most recent change of +$101.24 million (+1428.59%) on December 31, 2024.
- Over the past year, VRNA quarterly CFF has increased by +$70.14 million (+292.12%).
- VRNA quarterly CFF is now -50.02% below its all-time high of $188.39 million, reached on September 30, 2020.
Performance
VRNA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$250.78 M
+$70.14 M+38.83%
December 31, 2024
Summary
- As of March 10, 2025, VRNA TTM cash flow from financing activities is $250.78 million, with the most recent change of +$70.14 million (+38.83%) on December 31, 2024.
- Over the past year, VRNA TTM CFF has increased by +$157.91 million (+170.04%).
- VRNA TTM CFF is now at all-time high.
Performance
VRNA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VRNA Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +170.0% | +292.1% | +170.0% |
3 y3 years | +4199.7% | +292.1% | +170.0% |
5 y5 years | +100.0% | +292.1% | +170.0% |
VRNA Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +4199.7% | -43.6% | +1428.6% | at high | +3764.8% |
5 y | 5-year | at high | +4199.7% | -50.0% | +1428.6% | at high | +3764.8% |
alltime | all time | at high | +4199.7% | -50.0% | +1428.6% | at high | +3764.8% |
Verona Pharma Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $250.78 M(+170.0%) | $94.16 M(-1428.6%) | $250.78 M(+38.8%) |
Sep 2024 | - | -$7.09 M(-104.2%) | $180.63 M(-3.8%) |
Jun 2024 | - | $166.83 M(-5442.0%) | $187.77 M(+791.5%) |
Mar 2024 | - | -$3.12 M(-113.0%) | $21.06 M(-77.3%) |
Dec 2023 | $92.87 M(-34.1%) | $24.01 M(>+9900.0%) | $92.87 M(+29.9%) |
Sep 2023 | - | $48.00 K(-61.3%) | $71.47 M(-66.1%) |
Jun 2023 | - | $124.00 K(-99.8%) | $211.04 M(+0.4%) |
Mar 2023 | - | $68.69 M(+2527.6%) | $210.23 M(+49.3%) |
Dec 2022 | $140.82 M(-2402.1%) | $2.61 M(-98.1%) | $140.82 M(+2.6%) |
Sep 2022 | - | $139.62 M(<-9900.0%) | $137.30 M(-3422.1%) |
Jun 2022 | - | -$689.00 K(-5.1%) | -$4.13 M(-39.6%) |
Mar 2022 | - | -$726.00 K(-19.4%) | -$6.84 M(+11.9%) |
Dec 2021 | -$6.12 M(-103.2%) | -$901.00 K(-50.4%) | -$6.12 M(+383.2%) |
Sep 2021 | - | -$1.82 M(-46.5%) | -$1.27 M(-100.7%) |
Jun 2021 | - | -$3.40 M(<-9900.0%) | $188.94 M(-1.8%) |
Mar 2021 | - | $0.00(-100.0%) | $192.34 M(0.0%) |
Dec 2020 | $192.34 M(>+9900.0%) | $3.95 M(-97.9%) | $192.34 M(+1.9%) |
Sep 2020 | - | $188.39 M(>+9900.0%) | $188.76 M(>+9900.0%) |
Jun 2020 | - | $0.00(0.0%) | $212.90 K(+94.3%) |
Mar 2020 | - | $0.00(-100.0%) | $109.60 K(>+9900.0%) |
Dec 2019 | $0.00 | $372.00 K(-333.8%) | $0.00(-100.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2019 | - | -$159.10 K(+54.0%) | -$372.00 K(+74.7%) |
Jun 2019 | - | -$103.30 K(-5.7%) | -$212.90 K(+94.3%) |
Mar 2019 | - | -$109.60 K(<-9900.0%) | -$109.60 K(<-9900.0%) |
Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
Sep 2018 | - | $0.00(0.0%) | $742.00 K(-73.7%) |
Jun 2018 | - | $0.00(0.0%) | $2.82 M(-96.8%) |
Mar 2018 | - | $0.00(-100.0%) | $86.79 M(+1.5%) |
Dec 2017 | $85.47 M(+68.1%) | $742.00 K(-64.3%) | $85.47 M(+0.9%) |
Sep 2017 | - | $2.08 M(-97.5%) | $84.73 M(+2.5%) |
Jun 2017 | - | $83.97 M(-6455.3%) | $82.65 M(-6355.3%) |
Mar 2017 | - | -$1.32 M | -$1.32 M |
Dec 2016 | $50.84 M(>+9900.0%) | - | - |
Dec 2015 | $0.00(-100.0%) | - | - |
Dec 2014 | $20.39 M(+586.2%) | - | - |
Dec 2013 | $2.97 M(+81.3%) | - | - |
Dec 2012 | $1.64 M(-50.2%) | - | - |
Dec 2011 | $3.29 M(+144.2%) | - | - |
Dec 2010 | $1.35 M(-58.5%) | - | - |
Dec 2009 | $3.25 M(-8.9%) | - | - |
Dec 2008 | $3.57 M(+6.6%) | - | - |
Dec 2006 | $3.35 M(+104.2%) | - | - |
Dec 2005 | $1.64 M | - | - |
FAQ
- What is Verona Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Verona Pharma?
- What is Verona Pharma annual CFF year-on-year change?
- What is Verona Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Verona Pharma?
- What is Verona Pharma quarterly CFF year-on-year change?
- What is Verona Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Verona Pharma?
- What is Verona Pharma TTM CFF year-on-year change?
What is Verona Pharma annual cash flow from financing activities?
The current annual CFF of VRNA is $250.78 M
What is the all time high annual CFF for Verona Pharma?
Verona Pharma all-time high annual cash flow from financing activities is $250.78 M
What is Verona Pharma annual CFF year-on-year change?
Over the past year, VRNA annual cash flow from financing activities has changed by +$157.91 M (+170.04%)
What is Verona Pharma quarterly cash flow from financing activities?
The current quarterly CFF of VRNA is $94.16 M
What is the all time high quarterly CFF for Verona Pharma?
Verona Pharma all-time high quarterly cash flow from financing activities is $188.39 M
What is Verona Pharma quarterly CFF year-on-year change?
Over the past year, VRNA quarterly cash flow from financing activities has changed by +$70.14 M (+292.12%)
What is Verona Pharma TTM cash flow from financing activities?
The current TTM CFF of VRNA is $250.78 M
What is the all time high TTM CFF for Verona Pharma?
Verona Pharma all-time high TTM cash flow from financing activities is $250.78 M
What is Verona Pharma TTM CFF year-on-year change?
Over the past year, VRNA TTM cash flow from financing activities has changed by +$157.91 M (+170.04%)